Search alternatives:
ns decrease » _ decrease (Expand Search), we decrease (Expand Search), use decreased (Expand Search)
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
10 ns » 100 ns (Expand Search), 10 nm (Expand Search), 10 ng (Expand Search)
ns decrease » _ decrease (Expand Search), we decrease (Expand Search), use decreased (Expand Search)
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
10 ns » 100 ns (Expand Search), 10 nm (Expand Search), 10 ng (Expand Search)
-
121
-
122
VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival.
Published 2018“…The overall median rank of VRK1 mRNA overexpression was 947 (out of 19,273 measured genes) (p = 3.64x10<sup>-28</sup>). Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10<sup>-5</sup>), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10<sup>-5</sup>), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10<sup>-22</sup>), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10<sup>-71</sup>), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10<sup>-28</sup>), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10<sup>-12</sup>), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10<sup>-10</sup>) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10<sup>-17</sup>). …”
-
123
-
124
-
125
-
126
-
127
-
128
Maternal Hypoxia Decreases Capillary Supply and Increases Metabolic Inefficiency Leading to Divergence in Myocardial Oxygen Supply and Demand
Published 2015“…Hearts of male offspring subjected to Maternal Hypoxia showed a 20% decrease in cardiac output (<i>P</i><0.05), despite recording a 2-fold increase in glucose oxidation (<i>P</i><0.01) and 2.5-fold increase (<i>P</i><0.01) in palmitate oxidation. …”
-
129
(R+S) and (R)-albuterol decrease NF-κB activity
Published 2011“…After transfection, (R)-albuterol (R), (S)-albuterol (S), or racemic albuterol (R+ S) were added to cells pre-activated with (ConA, 5 μg/ml) and (PMA, 100 ng/ml) (CP) and then treated with (R)-, (S)-, or (R+S)-albuterol (Fig. 6). …”
-
130
Mutational analysis of GBV-C 152–167 NS5A peptide.
Published 2013“…HIV replication was significantly decreased in Jurkat cell lines expressing full-length NS5A (1–414), the 152–167 peptide, and the S158E mutant (*) compared to all other cell lines on days 5, 6, and 7 days post-infection (panel C). …”
-
131
-
132
-
133
-
134
-
135
(R)-albuterol decreases cytokine protein levels in activated T cells
Published 2011“…</p><p></p> (R)-albuterol, (S)-albuterol or racemic albuterol (R + S) at a dose (10M) were added to T (EL-4) cells pre-activated with mitogens Concanavalin A (Con A, 5 μg/ml) and phorbol myristate acetate (PMA, 100 ng/ml) (CP). …”
-
136
(R)-albuterol decreases cytokine levels in activated murine splenocytes
Published 2011“…</p><p></p> (R)-albuterol (R), (S)-albuterol (S) or racemic albuterol (R + S) at a dose (10M) were added to murine splenocytes pre-activated with mitogens Concanavalin A (Con A, 5 μg/ml) and phorbol myristate acetate (PMA, 100 ng/ml) (CP), (Fig 3 A, B). …”
-
137
-
138
-
139
-
140